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Abstract
Purpose Anemia in cancer patients can be treated with red
blood cell (RBC) transfusions. The patient burden associated
with a treatment in terms of total time spent is an important
factor to consider when measuring the benefits and challenges
of a therapy. This study estimates the time-related patient
burden associated with outpatient RBC transfusion.
Methods A retrospective chart review of outpatient cancer
patients receiving a RBC transfusion was conducted at 10
US centers. RBC transfusion time was measured as time
elapsed from pre- to post-transfusion vital sign assessment
and from transfusion start to stop time. Elapsed time from
hemoglobin level testing and blood draw for cross-match to
transfusion, estimated travel time and distance, and clinical
and demographic data were also collected.
Results Data from 110 patients (48.2 % male; mean age 64±
12 years) showed that the mean elapsed time between pre- and
post-vital sign assessment was 4.2 h (95 % confidence interval
(CI), 3.64–4.81) including 3.6 h (95%CI, 3.0–4.1) on average
to receive the actual RBC transfusion treatment. Hemoglobin
level testing (mean Hg level, 8.33 g/dL±0.67) and blood
drawn for cross-match were completed in an average of
31.2 h (95 % CI, 17.0–45.5) and 18.2 h (95 % CI, 12.1–
24.2) prior to transfusion, respectively. Patient one-way travel
time averaged 30.0 min (95 % CI, 25.9–34.3).
Conclusions In the US, CIA patients experience an important
time burden when being treated with RBC transfusion in
addition to the burden already added by chemotherapy.
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Introduction
Anemia is defined as a deficiency in the concentration of
hemoglobin containing red blood cells (RBCs). Anemia
symptoms including fatigue, dizziness, shortness of breath,
palpitations and cardiovascular complications, depression,
and impaired immune function can negatively impact patient
functional capacity and worsen patient health-related quality
of life [1, 2]. Anemia incidence can be as high as 90 % in
cancer patients receiving chemotherapy, radiation therapy, or
both [3–5]. Anemia is a common complication in cancer
patients receiving concomitantly administered chemotherapy
(subsequently called chemotherapy-induced anemia; CIA)
[3]. CIA results from direct effects of chemotherapy on
bone marrow function and renal function, which impair
the production of RBC [3]. Standard treatments for CIA
patients include RBC transfusion, iron therapy, and medication
to stimulate formation of RBC [4].
Multiple publications provide an assessment of the time
burden associated with receiving erythropoietin-stimulating
agents (ESA) therapy (specifically epoetin alpha and darbe-
poetin alfa [6, 7]) and only certain studies reported RBC
transfusion time burden from site perspective. In fact, one
single study conducted in Canada prospectively examined
the “chair time” for 44 RBC transfusions in 38 patients
while another single-center study retrospective chart review
in the US assessed the transfusion time for 100 transfusions
among 36 patients (19 patients with CIA) [8, 9]. Although
these studies estimate the time required for outpatient
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transfusion, these published studies estimate the time burden
from a site perspective and they are produced from single-
center studies. No research studies specifically aimed at esti-
mating the patient time burden of RBC transfusion to treat
CIA in multiple centers have been identified.
This study was undertaken to estimate the patient burden
in terms of time spent that is associated with outpatient RBC
transfusion treatment indicated for anemia caused by
concomitantly administered chemotherapy in patients
with non-myeloid malignancies.
Methods
A retrospective chart review study was implemented to
collect and summarize patient data reflecting patient burden
in terms of the time spent associated with outpatient RBC
transfusions indicated for CIA in patients with non-myeloid
malignancies.
Study design
This study is a multi-center, cross-sectional, retrospective
chart review study that was conducted at 10 US sites.
Transfusion centers that administer RBC transfusion indicated
for CIA in the outpatient setting that routinely document the
time the patients spend at the site in pre-transfusion and post-
transfusion vital signs assessment activities were considered
for participation in this study. In addition, potential sites
underwent a feasibility assessment in which site enrollment
eligibility criteria including size of patient population and
availability of patient medical records were evaluated.
At each participating center, patients with a diagnosis of
non-myeloid malignancy undergoing RBC transfusion to
treat their CIA were identified, screened, and recruited to
be included in this study. Eligible patients’ medical records
that document patient and treatment characteristics and time
spent in clinic during a patient’s transfusion visit were used
to quantify the outpatient RBC transfusion treatment time.
Anonymized data from the patient’s medical records was
abstracted by local site study staff, recorded on paper
case report forms (CRFs), and entered at the site into an
electronic data capture (EDC) system. The study protocol was
approved by the appropriate IRB in the USA and waiver of
patient consent was obtained. Also, this study was conducted
according to the recommendations of the Declaration of
Helsinki [10].
Using a site-specific chart identification algorithm, study
sites identified all patients with a diagnosis of non-myeloid
malignancy who received an outpatient RBC transfusion
indicated for CIA within a 3-month eligibility period from
August 01, 2010 to October 31, 2010. Each patient identified
was entered into an anonymized electronic enrollment log,
assignedwith a study identification number and uploaded to
a secure, password-protected EDC system designed and
managed by the StudyCoordinating Center (United BioSource
Corporation, Lexington, USA). All patients identified were
randomly selected using the EDC system, and a preliminary
cohort of patients was identified. Only the first eligible RBC
transfusion visit per patient was considered. In the order of the
EDC system randomization, the site reviewed the chart of the
patients listed in the preliminary target cohort to confirm
study eligibility using the screening form. To be included
in the study, patients were required to have a diagnosis
of non-myeloid malignancy (including all solid tumors,
non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, chronic
lymphocytic leukemia, and multiple myeloma), have received
a RBC transfusion indicated for CIA (as documented in the
patient medical chart) that was initially planned to occur in the
outpatient setting, and be 18 years of age or greater at time
of RBC transfusion. Patients with a diagnosis of acute
leukemias, chronic myelogenous leukemia, myelodysplastic
syndromes, or marrow fibrosis were excluded from the study.
Also, given that study data were collected from the patient’s
medical chart, electronic or paper medical record of the patient
needed to be available for review and abstraction by the study
site staff. Finally, patients were excluded if they had received
other therapies besides their RBC transfusion during the same
visit as the RBC transfusion visit (excluding diphenhydramine
[Benadryl], corticosteroids, ESA, or acetaminophen within
the time the patient arrived for their transfusion and the time
they left the facility). Patients were screened for eligibility
until a total target cohort of approximately 11 eligible patients
were identified at the site, for a total of 110 patients among
all sites.
Data collection and study endpoints
For all eligible patients, demographic and clinical data as
well as the date and time of pre-determined activities in
relation to a patient’s transfusion visit was collected from
the patient’s medical chart, recorded on paper CRF, and
entered into EDC system by site study staff. Site study staff
also had to complete a site questionnaire regarding study site
location, geographic setting, facility type, profit status,
teaching status, as well as number of outpatient transfusion
beds/chairs at the site and number of transfusions that can be
performed at one time at the site.
The primary endpoints for this study are related to
the time spent by patients undergoing RBC transfusion
treatment measured by the time from pre-transfusion vital signs
assessment to post-transfusion vital signs assessment at the
transfusion center as well as the outpatient RBC transfusion
time (transfusion start time and transfusion stop time).
The secondary endpoints for this study include the elapsed
time (in hours) from pre-transfusion hemoglobin level testing
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to transfusion, calculated from date and time of hemoglobin
level testing and date and time of start of RBC transfusion;
elapsed time (in hours) from blood draw for cross-match to
transfusion, calculated from date and time of blood draw for
cross-match and date and time of start of RBC transfusion;
number of RBC transfusion visits over the course of the most
recent year; time spent traveling (in minutes) and distance
traveled (in miles) between transfusion center and the patient’s
residence on the day of the RBC transfusion visit. MapQuest
mapping software [11] and patient address information
were used to calculate the time and distance traveled.
To be conservative, with respect to the time component of the
travel burden, the fastest route was assumed for purposes of
calculating distance and time for all patients.
The following exploratory endpoints for secondary
objectives were also considered: pre-transfusion hemoglobin
levels (level at time oncologist’s transfusion order was made,
if available) and location, site of blood drawn for cross-match,
and number of blood units ordered and transfused. Our study
also aimed to explore transfusion reactions and hospitalization
during or after the RBC transfusion. However, no transfusion
reactions were reported and hospitalization was only reported
for one patient in our study.
Statistical analyses
All enrolled patients were included in the analysis. The unit of
analysis for this study is the patient; only one RBC transfusion
visit was included per patient. The analyses of the patient
demographic and clinical characteristics (specifically, age,
gender, race, and type of malignancy) and primary and
secondary endpoints are descriptive of patient time burden
associated with RBC transfusion indicated for CIA. The
analyses for these primary, secondary and exploratory end-
points were descriptive summary methods including mean,
median, standard deviation, and range for continuous variables
and tables with percentages for categorical variables. Where
appropriate, 95 % confidence intervals (CI) for the mean level
over all patients were also completed.
Results
Patient population
A total of 380 patients with a diagnosis of non-myeloid
malignancy who received an outpatient RBC transfusion
indicated for CIA were identified within the 3-month
eligibility period from August 01, 2010 to October 31,
2010. From these patients, a total of 186 patients were
randomly selected and screened for participation in the
study; a total 110 patients met all the study eligibility
criteria and therefore were found eligible and included
in the final study cohort (mean number of 11 patients
per site; minimum 6 patients, maximum 19 patients).
Demographic and clinical characteristics of the final
study cohort are summarized in Table 1. The mean age
was 64±12 years (range 28–84 years). About 48 % of the
study participants were male, with 74.5 % being white/
Caucasian, 16.4 % Hispanic or Latino/Latin American,
and 9.1 % African American. The most common cancer
diagnoses were lung cancer (24.5 %), non-Hodgkin lym-
phoma (20.9 %), breast cancer (10.9 %), and gastrointesti-
nal/colorectal cancer (9.1 %). Data on pre-transfusion
hemoglobin level was reported for 108 patients (98 %).
Among those patients, 29 (26.4 %) patients had hemoglobin
level below 8 g/dL before transfusion, 73 (66.4 %) patients
had hemoglobin level between 8.0 and 9.5 g/dL, and 6
(5.5 %) patients had hemoglobin level between 9.5 and
13 g/dL (mean hemoglobin level, 8.33 g/dL±0.67). Among
all patients, a total of 216 blood units were ordered while a
total of 211 blood units were transfused (difference of 5
blood units). A total of 17 (15.5 %) patients were ordered
1 unit, 81 (73.6 %) were ordered 2 units, 11 (10.0 %) were
ordered 3 units, and only 1 patient (0.9 %) were ordered at
least 4 units. A total of 20 (18.2 %) patients had 1 unit
transfused, 80 (72.7 %) patients had 2 units transfused, 9
(8.2 %) had 3 units transfused, and only 1 patient (0.9 %)
had at least 4 units transfused.
Study sites
A total of 10 US sites from different states (Kentucky,
Ohio, California, Connecticut, Louisiana, Maryland,
Texas, and Alabama) were recruited to participate in
the study. Of the 10 participating sites, six sites are
outpatient hospitals and four are oncologist office/private
practice. Most of the sites (six sites) are located in
urban area while two sites are located in suburban area
and two sites in rural area. The majority of the sites
(seven sites) are considered profit organization and six
sites are considered as teaching centers. Among all
sites, the mean number of outpatient transfusion beds/
chairs at the site was 14±18 beds/chairs and the maximum
number of transfusions that can be performed at one
time at the site was 7±6 transfusions.
Patient time burden
This study collected data to assess the patient time burden
associated with the RBC transfusion treatment as well as
with clinical tests being performed pre-RBC transfusion
treatment and with travel to the clinic to receive RBC
transfusion. The duration of RBC transfusion as well as
the time intervals between transfusion-related activities are
presented in Table 2.
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RBC transfusion treatment
The patient direct time burden associated with RBC trans-
fusion treatment was measured by collecting the time from
pre-transfusion vital signs assessment and time for post-
transfusion vital signs assessment. Time for pre- and post-
transfusion vital signs assessments were reported for a total
of 98 patients (89 %). For those patients, the mean elapsed
time between pre-transfusion vital signs assessment to post-
transfusion vital signs assessment is 4.2 h (95 % CI, 3.64–
4.81), including 3.6 h (95 % CI, 3.0–4.1) in average to
receive the actual RBC transfusion treatment. Considering
that patients had a mean (±SD) of 1.9±0.5 blood units
transfused, this suggests that patients spent 1.9 h in average
per blood unit transfused per transfusion. The number of
RBC transfusions experienced over the course of the most
recent year was reported for 100 patients (91 %). In this
study cohort, 42.0 % of patients had one transfusion over
the most recent year, 16.0 % had two transfusions, 28.0 % had
three to five transfusions, and 14.0 % patients had more
than five transfusions. Considering that the median number of
RBC transfusion experienced during the most recent year was
Table 1 Demographic and
clinical characteristics of
study cohort
aData on type of malignancy was
reported to be missing from the
medical chart for one patient
Characteristics Characteristics
All patients (%) 110 (100%) All patients (%) 110 (100%)
Age (years) Hb level, n (%)
Mean±SD 64±12 Below 8 g/dL 29 (26.4 %)
Median 67 8.0–9.5 g/dL 73 (66.4 %)
Range 28–84 >9.5–13 g/dL 6 (5.5 %)
Gender, n (%) Hg level unknown 2 (2 %)
Male, n (%) 53 (48.2 %) Blood units ordered, n (%)
Female, n (%) 57 (51.8 %) 1 unit 17 (15.5 %)
Race, n (%) 2 units 81 (73.6 %)
White/Caucasian including
Arab/Middle Eastern
82 (74.5 %) 3 units 11 (10.0 %)
Hispanic or Latino/Latin American 18 (16.4 %) 4+units 1 (0.9 %)
Black or African American 10 (9.1 %) Blood units transfused, n (%)
Malignancy, n (%) 1 unit 20 (18.2 %)
Breast 12 (10.9 %) 2 units 80 (72.7 %)
Head/neck 3 (2.7 %) 3 units 9 (8.2 %)
Gastrointestinal/colorectal 10 (9.1 %) 4+units 1 (0.9 %)
Lung 27 (24.5 %)
Gynecological 9 (8.2 %)
Urological 3 (2.7 %)
Non-Hodgkin’s lymphoma 23 (20.9 %)
Multiple myeloma 7 (6.4 %)
Chronic lymphocytic leukemia 2 (1.8 %)
Other 13 (11.8 %)
Unknowna 1 (0.9 %)
Table 2 Patient RBC transfusion
time burden Pre-RBC transfusion visit time (hours) Mean SE Range 95 % CI
Hemoglobin level testing to transfusion 31.2 6.3 0.88–120.8 17.0–45.5
Blood draw for cross-match to transfusion 18.2 2.6 0.88–67.3 12.1–24.2
RBC transfusion elapsed time (hours)
Pre- to post-vital signs assessment time 4.2 0.2 1.75–6.9 3.6–4.8
RBC transfusion start time to stop time 3.6 0.2 1.1–6.4 3.0–4.1
Travel burden
Distance (miles) 21.5 2.7 0.8–120.0 14.9–28.2
Time (hours) 30.0 2.1 2.0–140.0 25.9–34.0
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2.0 and that patients spent 3.6 h in average to receive their
actual RBC transfusion, this represents up to a total of 7.2 h
per year spent in relation to the administration of RBC trans-
fusion only.
Pre-RBC transfusion treatment
Time of the pre-transfusion hemoglobin testing and time of
start of transfusion was reported for a total of 98 patients
(89 %). The mean elapsed time between pre-transfusion
hemoglobin test and start of RBC transfusion is 31.24 h
(95 % CI, 17.0–45.5). The results indicate that patients
had to wait from 0.88 to 120.80 h (median hours,
22.36) between pre-transfusion hemoglobin test and start
of RBC transfusion. From the total number of patients,
38 (34.5 %) patients went to an outpatient hospital to
have their hemoglobin level test performed while 68
(61.8 %) patients went to an oncologist office/private
practice setting and only one (0.9 %) patient went to a
transfusion center laboratory (data on site location not
reported for one patient).
Time of the blood draw for cross-match and time of start
of RBC transfusion was reported for a total of 81 patients
(73.6 %). The mean elapsed time between blood draw for
cross-match and start of RBC transfusion is 18.2 h (95 % CI,
12.1–24.2). The results indicate that patients had to wait
from 0.88 to 67.33 h (median 20.4 h) between blood draw
for cross-match and start of RBC transfusion. To be noted is
that this time overlaps with the elapse time between hemo-
globin test and start of RBC transfusion. Among all patients,
79 (71.8 %) patients went to an outpatient hospital setting
for their blood drawn for cross-match, 22 (20.0 %) patients
went to an oncologist office/private practice setting, and 9
(8.2 %) patients went to a transfusion center laboratory
setting.
Patient travel
The patient’s one-way travel to outpatient center during
RBC transfusion day was also considered to be a factor on
patient time burden. Data on distance traveled was reported
for a total of 102 patients (93 %) while data on travel time
was reported for all patients. The results show that patients
have to travel for a mean distance of 21.5 miles (95 % CI,
14.9–28.2) from their residence to the RBC transfusion
center on the day of the RBC transfusion visit. The largest
category of study patients (27.5 %) traveled between 15 and
25 miles, and 19.6 % had to travel between 25 and 50 miles.
The mean traveling time to transfusion center is 30.0 min
(95 % CI, 25.9–34.3). The largest category of study patients
(33.6 %) traveled between 25 and 50 min between the
transfusion center and their residence on the day of the
RBC transfusion visit.
Discussion
To our knowledge, this is the first multi-center study doc-
umenting the patient time burden of RBC transfusions to
treat CIA. Results from this study on 110 patients demon-
strated that patients had to spend 4.2 h (95 % CI, 3.64–4.81)
between pre- and post-vital sign assessment, including 3.6 h
to receive their actual RBC transfusion. Two published
studies estimating burden from a site perspective have
reported patient time for RBC transfusion [8, 9]. One
single-center study conducted in Canada prospectively ex-
amined “chair time” (defined as the time difference between
the admission of each patient into care to their time of
discharge) through time and motion methodology for 44
RBC transfusion visits. The reported average chair time
was 231 min (±47 min) with an average of 2.2 units trans-
fused (corresponding to mean chair time per unit of blood of
109±19 min) [8]. The retrospective chart review single-
center study by Ueno et al. [9] conducted a study including
20 CIA patients and reported a mean transfusion duration of
103 (±18.6) and 102 (±18.3) min for the first and second
units respectively and for the 2-unit visits, a mean duration
between units of 18 (±10.0) min. Thus, the total average
transfusion time reported time for a 2-unit transfusion (time
from first unit through the end of the second unit) was
223 min (±54) or 3.7 h, essentially similar to the transfusion
time of 3.6 h (for 2.0 units in average) we are reporting here.
While there are estimates of patient time required for
outpatient transfusion visits, these estimates are limited
strictly to the procedure time and do not account for other
clinical tests, multiple visits, and travel to site. Our study has
taken into account the elapsed time between hemoglobin
testing and blood draw for cross-match and RBC transfu-
sion, tests that were completed in an average of 31.24 h
(95 % CI, 17.0–45.5) and 18.20 h (95 % CI, 17.0–45.5)
prior to transfusion, respectively. These results demonstrate
patient waiting time after their blood tests to receive their
RBC transfusion. Although this study demonstrates such
delay, it does not allow identifying the potential delay fac-
tors such as delay for the Hb level result to be available to
the physician or delay in scheduling the patient’s RBC
transfusion visit. Also, 33.6 % of patients traveled 25 to
50 min between the transfusion center and their residence
during each day of the RBC transfusion visit. Traveling such
distance can be very inconvenient for the patient, especially
if they rely on public transportation, and can be a source of
stress which certainly contributes to patient burden [12].
Such results are important to assess the patient burden
because when all activities are taken into account and consid-
ering that 14.0 % of patients had more than five transfusions
over a 1-year period in our study, these times spent by the
patients in relation to RBC transfusion are considerable and
can certainly have an impact on the patient’s quality of life.
Support Care Cancer (2013) 21:1335–1340 1339
We should also consider that this time burden is in addition to
the time burden of chemotherapy treatment that those patients
with cancer must undergo, which was estimated to 5.7±6.9 h
in a published retrospective survey study [13].
This study has several potential limitations and risks, asso-
ciated with conducting chart review studies, such as abstraction
errors, no control over time reported in the chart, missing data,
and variation in abstraction methods. These were addressed in
this study by pre-screening of study sites to ensure that patient
medical records maintained at the site contain the requisite data
for completion of the forms, thorough training of the study site
staff on the protocol, CRF and EDC data entry procedures, use
of one study staff person to perform the data abstraction at each
site, programming of validation rules and edit checks in the
EDC system, and regular monitoring of data entered to ensure
data quality and adequate sample size to account for the
possibility of missing data.
Conclusion
In conclusion, this study provides data on the patient time
burden associated with RBC transfusion treatment. CIA
patients experience substantial time burden when being
treated with RBC transfusion in addition to the burden
already compromised by chemotherapy.
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